Brighton Jones LLC Purchases Shares of 8,111 Teleflex Incorporated $TFX

Brighton Jones LLC acquired a new position in shares of Teleflex Incorporated (NYSE:TFX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,111 shares of the medical technology company’s stock, valued at approximately $992,000.

Other large investors also recently modified their holdings of the company. Thurston Springer Miller Herd & Titak Inc. raised its position in Teleflex by 242.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock valued at $26,000 after buying an additional 153 shares during the last quarter. True Wealth Design LLC boosted its holdings in Teleflex by 10,333.3% during the 2nd quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock worth $37,000 after acquiring an additional 310 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Teleflex by 43.1% in the 2nd quarter. Parallel Advisors LLC now owns 455 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 137 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Teleflex by 30.2% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock valued at $77,000 after purchasing an additional 129 shares during the last quarter. Finally, CX Institutional lifted its position in shares of Teleflex by 14.7% during the second quarter. CX Institutional now owns 872 shares of the medical technology company’s stock valued at $103,000 after purchasing an additional 112 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Trading Up 0.0%

Shares of TFX opened at $122.33 on Thursday. Teleflex Incorporated has a fifty-two week low of $102.58 and a fifty-two week high of $185.94. The business has a 50-day moving average of $120.22 and a 200 day moving average of $121.04. The firm has a market cap of $5.41 billion, a P/E ratio of -16.64, a price-to-earnings-growth ratio of 1.46 and a beta of 0.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.38 by $0.29. The firm had revenue of $892.90 million during the quarter, compared to analyst estimates of $892.79 million. Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. During the same quarter last year, the business earned $3.49 earnings per share. The company’s quarterly revenue was up 19.4% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. As a group, research analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 15th. Shareholders of record on Friday, November 14th were given a dividend of $0.34 per share. The ex-dividend date was Friday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. Teleflex’s dividend payout ratio is currently -18.50%.

Analyst Ratings Changes

Several research firms have commented on TFX. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $135.00 price objective on shares of Teleflex in a research note on Wednesday, December 17th. Zacks Research lowered Teleflex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Tuesday, December 9th. Truist Financial upped their price objective on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research note on Thursday, December 18th. Finally, Wall Street Zen lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $142.43.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.